{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:33:48Z","timestamp":1790944428280,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T00:00:00Z","timestamp":1563580800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T00:00:00Z","timestamp":1563580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s12020-019-02018-4","type":"journal-article","created":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T06:02:23Z","timestamp":1563602543000},"page":"95-104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Novel thyroid hormones"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6450-3788","authenticated-orcid":false,"given":"Riccardo","family":"Zucchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Rutigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Saponaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,20]]},"reference":[{"key":"2018_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.mce.2017.01.025","volume":"458","author":"AH van der Spek","year":"2017","unstructured":"A.H. van der Spek, E. Fliers, A. Boelen, The classic pathways of thyroid hormone metabolism. Mol. Cell Endocrinol. 458, 29\u201338 (2017). \n                    https:\/\/doi.org\/10.1016\/j.mce.2017.01.025","journal-title":"Mol. Cell Endocrinol."},{"key":"2018_CR2","doi-asserted-by":"publisher","unstructured":"A.C. Bianco, A. Dumitrescu, B. Gereben, M.O. Ribeiro, T.L. Fonseca, G.W. Fernandes, B. Bocco, Paradigms of dynamic control of thyroid hormone signaling. Endocr. Rev. (2019). \n                    https:\/\/doi.org\/10.1210\/er.2018-00275","DOI":"10.1210\/er.2018-00275"},{"issue":"6","key":"2018_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1365-2265.1978.tb02187.x","volume":"8","author":"H Meinhold","year":"1978","unstructured":"H. Meinhold, P. Schurnbrand, A radioimmunoassay for 3,5-diiodothyronine. Clin. Endocrinol. 8(6), 493\u2013497 (1978)","journal-title":"Clin. Endocrinol."},{"issue":"9","key":"2018_CR4","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1089\/thy.2013.0688","volume":"24","author":"I Lehmphul","year":"2014","unstructured":"I. Lehmphul, G. Brabant, H. Wallaschofski, M. Ruchala, C.J. Strasburger, J. Kohrle, Z. Wu, Detection of 3,5-diiodothyronine in sera of patients with altered thyroid status using a new monoclonal antibody-based chemiluminescence immunoassay. Thyroid 24(9), 1350\u20131360 (2014). \n                    https:\/\/doi.org\/10.1089\/thy.2013.0688","journal-title":"Thyroid"},{"issue":"Suppl 1","key":"2018_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000381308","volume":"4","author":"M Pietzner","year":"2015","unstructured":"M. Pietzner, G. Homuth, K. Budde, I. Lehmphul, U. Volker, H. Volzke, M. Nauck, J. Kohrle, N. Friedrich, Urine metabolomics by (1)H-NMR spectroscopy indicates associations between serum 3,5-T2 concentrations and intermediary metabolism in euthyroid humans. Eur. Thyroid J. 4(Suppl 1), 92\u2013100 (2015). \n                    https:\/\/doi.org\/10.1159\/000381308","journal-title":"Eur. Thyroid J."},{"key":"2018_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3389\/fendo.2019.00088","volume":"10","author":"L Lorenzini","year":"2019","unstructured":"L. Lorenzini, N.M. Nguyen, G. Sacripanti, E. Serni, M. Borso, F. Saponaro, E. Cecchi, T. Simoncini, S. Ghelardoni, R. Zucchi, A. Saba, Assay of endogenous 3,5-diiodo-L-thyronine (3,5-T2) and 3,3\u2019-diiodo-L-thyronine (3,3\u2019-T2) in human serum: a feasibility study. Front Endocrinol. (Lausanne) 10, 88 (2019). \n                    https:\/\/doi.org\/10.3389\/fendo.2019.00088","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"20","key":"2018_CR7","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.1007\/s00216-016-9614-9","volume":"408","author":"M Hansen","year":"2016","unstructured":"M. Hansen, X. Luong, D.L. Sedlak, C.C. Helbing, T. Hayes, Quantification of 11 thyroid hormones and associated metabolites in blood using isotope-dilution liquid chromatography tandem mass spectrometry. Anal. Bioanal. Chem. 408(20), 5429\u20135442 (2016). \n                    https:\/\/doi.org\/10.1007\/s00216-016-9614-9","journal-title":"Anal. Bioanal. Chem."},{"key":"2018_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.chroma.2017.12.048","volume":"1534","author":"ZM Li","year":"2018","unstructured":"Z.M. Li, F. Giesert, D. Vogt-Weisenhorn, K.M. Main, N.E. Skakkebaek, H. Kiviranta, J. Toppari, U. Feldt-Rasmussen, H. Shen, K.W. Schramm, M. De Angelis, Determination of thyroid hormones in placenta using isotope-dilution liquid chromatography quadrupole time-of-flight mass spectrometry. J. Chromatogr. A 1534, 85\u201392 (2018). \n                    https:\/\/doi.org\/10.1016\/j.chroma.2017.12.048","journal-title":"J. Chromatogr. A"},{"issue":"8","key":"2018_CR9","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1210\/en.2013-1030","volume":"154","author":"A Mendoza","year":"2013","unstructured":"A. Mendoza, P. Navarrete-Ramirez, G. Hernandez-Puga, P. Villalobos, G. Holzer, J.P. Renaud, V. Laudet, A. Orozco, 3,5-T2 is an alternative ligand for the thyroid hormone receptor beta1. Endocrinology 154(8), 2948\u20132958 (2013). \n                    https:\/\/doi.org\/10.1210\/en.2013-1030","journal-title":"Endocrinology"},{"issue":"2","key":"2018_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/apha.12821","volume":"220","author":"S da Silva Teixeira","year":"2017","unstructured":"S. da Silva Teixeira, C. Filgueira, D.H. Sieglaff, C. Benod, R. Villagomez, L.J. Minze, A. Zhang, P. Webb, M.T. Nunes, 3,5-diiodothyronine (3,5-T2) reduces blood glucose independently of insulin sensitization in obese mice. Acta Physiol. 220(2), 238\u2013250 (2017). \n                    https:\/\/doi.org\/10.1111\/apha.12821","journal-title":"Acta Physiol."},{"issue":"2","key":"2018_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrendo.2015.205","volume":"12","author":"PJ Davis","year":"2016","unstructured":"P.J. Davis, F. Goglia, J.L. Leonard, Nongenomic actions of thyroid hormone. Nat. Rev. Endocrinol. 12(2), 111\u2013121 (2016). \n                    https:\/\/doi.org\/10.1038\/nrendo.2015.205","journal-title":"Nat. Rev. Endocrinol."},{"key":"2018_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3389\/fendo.2018.00427","volume":"9","author":"R Senese","year":"2018","unstructured":"R. Senese, P. de Lange, G. Petito, M. Moreno, F. Goglia, A. Lanni, 3,5-Diiodothyronine: a novel thyroid hormone metabolite and potent modulator of energy metabolism. Front Endocrinol. (Lausanne) 9, 427 (2018). \n                    https:\/\/doi.org\/10.3389\/fendo.2018.00427","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"2018_CR13","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3389\/fphys.2014.00528","volume":"5","author":"F Goglia","year":"2015","unstructured":"F. Goglia, The effects of 3,5-diiodothyronine on energy balance. Front Physiol. 5, 528 (2015)","journal-title":"Front Physiol."},{"issue":"3","key":"2018_CR14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1530\/JOE-13-0502","volume":"221","author":"AS Padron","year":"2014","unstructured":"A.S. Padron, R.A. Neto, T.U. Pantaleao, M.C. de Souza dos Santos, R.L. Araujo, B.M. de Andrade, M. da Silva Leandro, J.P. de Castro, A.C. Ferreira, D.P. de Carvalho, Administration of 3,5-diiodothyronine (3,5-T2) causes central hypothyroidism and stimulates thyroid-sensitive tissues. J. Endocrinol. 221(3), 415\u2013427 (2014). \n                    https:\/\/doi.org\/10.1530\/JOE-13-0502","journal-title":"J. Endocrinol."},{"issue":"1","key":"2018_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1210\/en.2014-1604","volume":"156","author":"W Jonas","year":"2015","unstructured":"W. Jonas, J. Lietzow, F. Wohlgemuth, C.S. Hoefig, P. Wiedmer, U. Schweizer, J. Kohrle, A. Schurmann, 3,5-Diiodo-L-thyronine (3,5-t2) exerts thyromimetic effects on hypothalamus-pituitary-thyroid axis, body composition, and energy metabolism in male diet-induced obese mice. Endocrinology 156(1), 389\u2013399 (2015). \n                    https:\/\/doi.org\/10.1210\/en.2014-1604","journal-title":"Endocrinology"},{"issue":"2","key":"2018_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000381543","volume":"4","author":"JW Dietrich","year":"2015","unstructured":"J.W. Dietrich, P. Muller, F. Schiedat, M. Schlomicher, J. Strauch, A. Chatzitomaris, H.H. Klein, A. Mugge, J. Kohrle, E. Rijntjes, I. Lehmphul, Nonthyroidal Illness syndrome in cardiac illness involves elevated concentrations of 3,5-diiodothyronine and correlates with atrial remodeling. Eur. Thyroid J. 4(2), 129\u2013137 (2015). \n                    https:\/\/doi.org\/10.1159\/000381543","journal-title":"Eur. Thyroid J."},{"issue":"4","key":"2018_CR17","first-page":"655","volume":"25","author":"A Antonelli","year":"2011","unstructured":"A. Antonelli, P. Fallahi, S.M. Ferrari, A. Di Domenicantonio, M. Moreno, A. Lanni, F. Goglia, 3,5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. J. Biol. Regul. Homeost. Agents 25(4), 655\u2013660 (2011)","journal-title":"J. Biol. Regul. Homeost. Agents"},{"issue":"2","key":"2018_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086890","volume":"9","author":"F van der Valk","year":"2014","unstructured":"F. van der Valk, C. Hassing, M. Visser, P. Thakkar, A. Mohanan, K. Pathak, C. Dutt, V. Chauthaiwale, M. Ackermans, A. Nederveen, M. Serlie, M. Nieuwdorp, E. Stroes, The effect of a diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomized controlled trial. PLoS ONE 9(2), e86890 (2014). \n                    https:\/\/doi.org\/10.1371\/journal.pone.0086890","journal-title":"PLoS ONE"},{"issue":"6","key":"2018_CR19","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nm1051","volume":"10","author":"TS Scanlan","year":"2004","unstructured":"T.S. Scanlan, K.L. Suchland, M.E. Hart, G. Chiellini, Y. Huang, P.J. Kruzich, S. Frascarelli, D.A. Crossley, J.R. Bunzow, S. Ronca-Testoni, E.T. Lin, D. Hatton, R. Zucchi, D.K. Grandy, 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat. Med 10(6), 638\u2013642 (2004). \n                    https:\/\/doi.org\/10.1038\/nm1051","journal-title":"Nat. Med"},{"key":"2018_CR20","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1089\/thy.2016.0178","volume":"26","author":"CS Hoefig","year":"2016","unstructured":"C.S. Hoefig, R. Zucchi, J. K\u00f6hrle, Thyronamines and derivatives: physiological relevance, pharmacological actions and future research directions. Thyroid 26, 1656\u20131673 (2016)","journal-title":"Thyroid"},{"issue":"10","key":"2018_CR21","doi-asserted-by":"publisher","first-page":"5063","DOI":"10.1210\/en.2010-0491","volume":"151","author":"A Saba","year":"2010","unstructured":"A. Saba, G. Chiellini, S. Frascarelli, M. Marchini, S. Ghelardoni, A. Raffaelli, M. Tonacchera, P. Vitti, T.S. Scanlan, R. Zucchi, Tissue distribution and cardiac metabolism of 3-iodothyronamine. Endocrinology 151(10), 5063\u20135073 (2010). \n                    https:\/\/doi.org\/10.1210\/en.2010-0491","journal-title":"Endocrinology"},{"issue":"11","key":"2018_CR22","doi-asserted-by":"publisher","first-page":"4356","DOI":"10.1210\/en.2014-1499","volume":"156","author":"CS Hoefig","year":"2015","unstructured":"C.S. Hoefig, T. Wuensch, E. Rijntjes, I. Lehmphul, H. Daniel, U. Schweizer, J. Mittag, J. Kohrle, Biosynthesis of 3-Iodothyronamine from T4 in murine intestinal tissue. Endocrinology 156(11), 4356\u20134364 (2015). \n                    https:\/\/doi.org\/10.1210\/en.2014-1499","journal-title":"Endocrinology"},{"issue":"2","key":"2018_CR23","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1210\/er.2018-00182","volume":"40","author":"J Kohrle","year":"2019","unstructured":"J. Kohrle, H. Biebermann, 3-Iodothyronamine-A thyroid hormone metabolite with distinct target profiles and mode of action. Endocr. Rev. 40(2), 602\u2013630 (2019). \n                    https:\/\/doi.org\/10.1210\/er.2018-00182","journal-title":"Endocr. Rev."},{"issue":"4","key":"2018_CR24","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1210\/en.2008-1339","volume":"150","author":"AG Ianculescu","year":"2009","unstructured":"A.G. Ianculescu, K.M. Giacomini, T.S. Scanlan, Identification and characterization of 3-iodothyronamine intracellular transport. Endocrinology 150(4), 1991\u20131999 (2009). \n                    https:\/\/doi.org\/10.1210\/en.2008-1339","journal-title":"Endocrinology"},{"issue":"3","key":"2018_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1530\/JOE-12-0055","volume":"213","author":"G Chiellini","year":"2012","unstructured":"G. Chiellini, P. Erba, V. Carnicelli, C. Manfredi, S. Frascarelli, S. Ghelardoni, G. Mariani, R. Zucchi, Distribution of exogenous [125I]-3-iodothyronamine in mouse in vivo: relationship with trace amine-associated receptors. J. Endocrinol. 213(3), 223\u2013230 (2012). \n                    https:\/\/doi.org\/10.1530\/JOE-12-0055","journal-title":"J. Endocrinol."},{"issue":"1","key":"2018_CR26","doi-asserted-by":"publisher","first-page":"E69","DOI":"10.1210\/jc.2011-1115","volume":"97","author":"E Galli","year":"2012","unstructured":"E. Galli, M. Marchini, A. Saba, S. Berti, M. Tonacchera, P. Vitti, T.S. Scanlan, G. Iervasi, R. Zucchi, Detection of 3-iodothyronamine in human patients: a preliminary study. J. Clin. Endocrinol. Metab. 97(1), E69\u2013E74 (2012). \n                    https:\/\/doi.org\/10.1210\/jc.2011-1115","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"2018_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1677\/JOE-10-0060","volume":"206","author":"MT Ackermans","year":"2010","unstructured":"M.T. Ackermans, L.P. Klieverik, P. Ringeling, E. Endert, A. Kalsbeek, E. Fliers, An online solid-phase extraction-liquid chromatography-tandem mass spectrometry method to study the presence of thyronamines in plasma and tissue and their putative conversion from 13C6-thyroxine. J. Endocrinol. 206(3), 327\u2013334 (2010). \n                    https:\/\/doi.org\/10.1677\/JOE-10-0060","journal-title":"J. Endocrinol."},{"issue":"6","key":"2018_CR28","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1210\/jc.2010-2680","volume":"96","author":"CS Hoefig","year":"2011","unstructured":"C.S. Hoefig, J. Kohrle, G. Brabant, K. Dixit, B. Yap, C.J. Strasburger, Z. Wu, Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. J. Clin. Endocrinol. Metab. 96(6), 1864\u20131872 (2011). \n                    https:\/\/doi.org\/10.1210\/jc.2010-2680","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"2018_CR29","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1089\/thy.2016.0214","volume":"26","author":"L Langouche","year":"2016","unstructured":"L. Langouche, I. Lehmphul, S.V. Perre, J. Kohrle, G. Van den Berghe, Circulating 3-T1AM and 3,5-T2 in critically Ill patients: a cross-sectional observational study. Thyroid 26(12), 1674\u20131680 (2016). \n                    https:\/\/doi.org\/10.1089\/thy.2016.0214","journal-title":"Thyroid"},{"issue":"4","key":"2018_CR30","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1210\/jc.2018-01466","volume":"104","author":"JL la Cour","year":"2019","unstructured":"J.L. la Cour, H.M. Christensen, J. Kohrle, I. Lehmphul, C. Kistorp, B. Nygaard, J. Faber, Association between 3-iodothyronamine (T1am) concentrations and left ventricular function in chronic heart failure. J. Clin. Endocrinol. Metab. 104(4), 1232\u20131238 (2019). \n                    https:\/\/doi.org\/10.1210\/jc.2018-01466","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"2018_CR31","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1089\/thy.2017.0111","volume":"27","author":"L Lorenzini","year":"2017","unstructured":"L. Lorenzini, S. Ghelardoni, A. Saba, G. Sacripanti, G. Chiellini, R. Zucchi, Recovery of 3-iodothyronamine and derivatives in biological matrixes: problems and pitfalls. Thyroid 27(10), 1323\u20131331 (2017). \n                    https:\/\/doi.org\/10.1089\/thy.2017.0111","journal-title":"Thyroid"},{"issue":"Suppl 1","key":"2018_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000430839","volume":"4","author":"M Coster","year":"2015","unstructured":"M. Coster, H. Biebermann, T. Schoneberg, C. Staubert, Evolutionary conservation of 3-iodothyronamine as an agonist at the trace amine-associated receptor 1. Eur. Thyroid J. 4(Suppl 1), 9\u201320 (2015). \n                    https:\/\/doi.org\/10.1159\/000430839","journal-title":"Eur. Thyroid J."},{"key":"2018_CR33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fphys.2014.00402","volume":"5","author":"R Zucchi","year":"2014","unstructured":"R. Zucchi, A. Accorroni, G. Chiellini, Update on 3-iodothyronamine and its neurological and metabolic actions. Front Physiol. 5, 402 (2014). \n                    https:\/\/doi.org\/10.3389\/fphys.2014.00402","journal-title":"Front Physiol."},{"issue":"1","key":"2018_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16593-x","volume":"7","author":"E Shinderman-Maman","year":"2017","unstructured":"E. Shinderman-Maman, K. Cohen, D. Moskovich, A. Hercbergs, H. Werner, P.J. Davis, M. Ellis, O. Ashur-Fabian, Thyroid hormones derivatives reduce proliferation and induce cell death and DNA damage in ovarian cancer. Sci. Rep. 7(1), 16475 (2017). \n                    https:\/\/doi.org\/10.1038\/s41598-017-16593-x","journal-title":"Sci. Rep."},{"key":"2018_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/BCTT.S178721","volume":"11","author":"E Tremmel","year":"2019","unstructured":"E. Tremmel, S. Hofmann, C. Kuhn, H. Heidegger, S. Heublein, K. Hermelink, R. Wuerstlein, N. Harbeck, D. Mayr, S. Mahner, N. Ditsch, U. Jeschke, A. Vattai, Thyronamine regulation of TAAR1 expression in breast cancer cells and investigation of its influence on viability and migration. Breast Cancer (Dove Med Press) 11, 87\u201397 (2019). \n                    https:\/\/doi.org\/10.2147\/BCTT.S178721","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"2018_CR36","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3389\/fphar.2017.00987","volume":"8","author":"G Rutigliano","year":"2017","unstructured":"G. Rutigliano, A. Accorroni, R. Zucchi, The case for TAAR1 as a modulator of central nervous system function. Front Pharm. 8, 987 (2017). \n                    https:\/\/doi.org\/10.3389\/fphar.2017.00987","journal-title":"Front Pharm."},{"issue":"11","key":"2018_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106923","volume":"9","author":"V Mariotti","year":"2014","unstructured":"V. Mariotti, E. Melissari, C. Iofrida, M. Righi, M. Di Russo, R. Donzelli, A. Saba, S. Frascarelli, G. Chiellini, R. Zucchi, S. Pellegrini, Modulation of gene expression by 3-iodothyronamine: genetic evidence for a lipolytic pattern. PLoS ONE 9(11), e106923 (2014). \n                    https:\/\/doi.org\/10.1371\/journal.pone.0106923","journal-title":"PLoS ONE"},{"key":"2018_CR38","doi-asserted-by":"publisher","unstructured":"F.M. Assadi-Porter, H. Reiland, M. Sabatini, L. Lorenzini, V. Carnicelli, M. Rogowski, E.S. Selen Alpergin, M. Tonelli, S. Ghelardoni, A. Saba, R. Zucchi, G. Chiellini, Metabolic reprogramming by 3-iodothyronamine (T1AM): a new perspective to reverse obesity through co-regulation of sirtuin 4 and 6 expression. Int. J. Mol. Sci. 19(5) (2018). \n                    https:\/\/doi.org\/10.3390\/ijms19051535","DOI":"10.3390\/ijms19051535"},{"key":"2018_CR39","doi-asserted-by":"publisher","unstructured":"E.S. Selen Alpergin, Z. Bolandnazar, M. Sabatini, M. Rogowski, G. Chiellini, R. Zucchi, F.M. Assadi-Porter, Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycystic ovary syndrome with 3-iodothyronamine. Physiol. Rep. 5(1) (2017). \n                    https:\/\/doi.org\/10.14814\/phy2.13097","DOI":"10.14814\/phy2.13097"},{"issue":"2","key":"2018_CR40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1476-5381.2012.02137.x","volume":"168","author":"ME Manni","year":"2013","unstructured":"M.E. Manni, G. De Siena, A. Saba, M. Marchini, E. Landucci, E. Gerace, M. Zazzeri, C. Musilli, D. Pellegrini-Giampietro, R. Matucci, R. Zucchi, L. Raimondi, Pharmacological effects of 3-iodothyronamine (T1AM) in mice include facilitation of memory acquisition and retention and reduction of pain threshold. Br. J. Pharm. 168(2), 354\u2013362 (2013). \n                    https:\/\/doi.org\/10.1111\/j.1476-5381.2012.02137.x","journal-title":"Br. J. Pharm."},{"issue":"12","key":"2018_CR41","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1002\/oby.20391","volume":"21","author":"JA Haviland","year":"2013","unstructured":"J.A. Haviland, H. Reiland, D.E. Butz, M. Tonelli, W.P. Porter, R. Zucchi, T.S. Scanlan, G. Chiellini, F.M. Assadi-Porter, NMR-based metabolomics and breath studies show lipid and protein catabolism during low dose chronic T(1)AM treatment. Obes. (Silver Spring) 21(12), 2538\u20132544 (2013). \n                    https:\/\/doi.org\/10.1002\/oby.20391","journal-title":"Obes. (Silver Spring)"},{"issue":"10","key":"2018_CR42","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1089\/thy.2017.0506","volume":"28","author":"A Laurino","year":"2018","unstructured":"A. Laurino, E. Landucci, F. Resta, G. De Siena, D.E. Pellegrini-Giampietro, A. Masi, G. Mannaioni, L. Raimondi, Anticonvulsant and neuroprotective effects of the thyroid hormone metabolite 3-iodothyroacetic acid. Thyroid 28(10), 1387\u20131397 (2018). \n                    https:\/\/doi.org\/10.1089\/thy.2017.0506","journal-title":"Thyroid"},{"issue":"6","key":"2018_CR43","first-page":"736","volume":"48","author":"J Lv","year":"2018","unstructured":"J. Lv, J. Liao, W. Tan, L. Yang, X. Shi, H. Zhang, L. Chen, S. Wang, Q. Li, 3-Iodothyronamine acting through an anti-apoptotic mechanism is neuroprotective against spinal cord injury in rats. Ann. Clin. Lab Sci. 48(6), 736\u2013742 (2018)","journal-title":"Ann. Clin. Lab Sci."},{"issue":"4","key":"2018_CR44","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10557-011-6320-x","volume":"25","author":"S Frascarelli","year":"2011","unstructured":"S. Frascarelli, S. Ghelardoni, G. Chiellini, E. Galli, F. Ronca, T.S. Scanlan, R. Zucchi, Cardioprotective effect of 3-iodothyronamine in perfused rat heart subjected to ischemia and reperfusion. Cardiovasc Drugs Ther. 25(4), 307\u2013313 (2011). \n                    https:\/\/doi.org\/10.1007\/s10557-011-6320-x","journal-title":"Cardiovasc Drugs Ther."},{"key":"2018_CR45","doi-asserted-by":"publisher","unstructured":"G. Chiellini, L. Bellusci, M. Sabatini, R. Zucchi, Thyronamines and analogues - the route from rediscovery to translational research on thyronergic amines. Mol. Cell Endocrinol. (2017). \n                    https:\/\/doi.org\/10.1016\/j.mce.2017.01.002","DOI":"10.1016\/j.mce.2017.01.002"},{"issue":"4","key":"2018_CR46","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1210\/endo-59-4-425","volume":"59","author":"P Jouan","year":"1956","unstructured":"P. Jouan, R. Michel, J. Roche, W. Wolf, The recovery of 3:5:3\u2019 -triiodothyroacetic acid and 3:3\u2019 -diiodothyronine from rat kidney after injection of 3:5:3\u2019 triiodothyronine. Endocrinology 59(4), 425\u2013432 (1956). \n                    https:\/\/doi.org\/10.1210\/endo-59-4-425","journal-title":"Endocrinology"},{"issue":"2","key":"2018_CR47","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1210\/endo-59-2-252","volume":"59","author":"EC Albright","year":"1956","unstructured":"E.C. Albright, H.A. Lardy, F.C. Larson, K. Tomita, Enzymatic conversion of thyroxine and triiodothyronine to the corresponding acetic acid analogues. Endocrinology 59(2), 252\u2013254 (1956). \n                    https:\/\/doi.org\/10.1210\/endo-59-2-252","journal-title":"Endocrinology"},{"issue":"381","key":"2018_CR48","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/pgmj.33.381.333","volume":"33","author":"JH Wilkinson","year":"1957","unstructured":"J.H. Wilkinson, Recent work on thyroid hormones. Post. Med J. 33(381), 333\u2013337 (1957). \n                    https:\/\/doi.org\/10.1136\/pgmj.33.381.333","journal-title":"Post. Med J."},{"issue":"2","key":"2018_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.mce.2011.10.024","volume":"349","author":"CS Hoefig","year":"2012","unstructured":"C.S. Hoefig, K. Renko, S. Piehl, T.S. Scanlan, M. Bertoldi, T. Opladen, G.F. Hoffmann, J. Klein, O. Blankenstein, U. Schweizer, J. Kohrle, Does the aromatic L-amino acid decarboxylase contribute to thyronamine biosynthesis? Mol. Cell Endocrinol. 349(2), 195\u2013201 (2012). \n                    https:\/\/doi.org\/10.1016\/j.mce.2011.10.024","journal-title":"Mol. Cell Endocrinol."},{"issue":"6","key":"2018_CR50","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1210\/en.2007-1678","volume":"149","author":"S Piehl","year":"2008","unstructured":"S. Piehl, T. Heberer, G. Balizs, T.S. Scanlan, R. Smits, B. Koksch, J. Kohrle, Thyronamines are isozyme-specific substrates of deiodinases. Endocrinology 149(6), 3037\u20133045 (2008). \n                    https:\/\/doi.org\/10.1210\/en.2007-1678","journal-title":"Endocrinology"},{"issue":"3","key":"2018_CR51","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1210\/jcem-67-3-480","volume":"67","author":"IJ Chopra","year":"1988","unstructured":"I.J. Chopra, R.J. Boado, D.L. Geffner, D.H. Solomon, A radioimmunoassay for measurement of thyronine and its acetic acid analog in urine. J. Clin. Endocrinol. Metab. 67(3), 480\u2013487 (1988). \n                    https:\/\/doi.org\/10.1210\/jcem-67-3-480","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"2018_CR52","doi-asserted-by":"publisher","first-page":"R99","DOI":"10.1530\/JOE-17-0113","volume":"234","author":"S Groeneweg","year":"2017","unstructured":"S. Groeneweg, R.P. Peeters, T.J. Visser, W.E. Visser, Triiodothyroacetic acid in health and disease. J. Endocrinol. 234(2), R99\u2013R121 (2017). \n                    https:\/\/doi.org\/10.1530\/JOE-17-0113","journal-title":"J. Endocrinol."},{"issue":"4","key":"2018_CR53","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1210\/jcem-50-4-712","volume":"50","author":"CS Pittman","year":"1980","unstructured":"C.S. Pittman, T. Shimizu, A. Burger, J.B. Chambers Jr., The nondeiodinative pathways of thyroxine metabolism: 3,5,3\u2019,5-tetraiodothyroacetic acid turnover in normal and fasting human subjects. J. Clin. Endocrinol. Metab. 50(4), 712\u2013716 (1980). \n                    https:\/\/doi.org\/10.1210\/jcem-50-4-712","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"14","key":"2018_CR54","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1111\/bph.12697","volume":"171","author":"C Musilli","year":"2014","unstructured":"C. Musilli, G. De Siena, M.E. Manni, A. Logli, E. Landucci, R. Zucchi, A. Saba, R. Donzelli, M.B. Passani, G. Provensi, L. Raimondi, Histamine mediates behavioural and metabolic effects of 3-iodothyroacetic acid, an endogenous end product of thyroid hormone metabolism. Br. J. Pharm. 171(14), 3476\u20133484 (2014). \n                    https:\/\/doi.org\/10.1111\/bph.12697","journal-title":"Br. J. Pharm."},{"key":"2018_CR55","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejphar.2015.04.038","volume":"761","author":"A Laurino","year":"2015","unstructured":"A. Laurino, G. De Siena, A. Saba, G. Chiellini, E. Landucci, R. Zucchi, L. Raimondi, In the brain of mice, 3-iodothyronamine (T1AM) is converted into 3-iodothyroacetic acid (TA1) and it is included within the signaling network connecting thyroid hormone metabolites with histamine. Eur. J. Pharm. 761, 130\u2013134 (2015). \n                    https:\/\/doi.org\/10.1016\/j.ejphar.2015.04.038","journal-title":"Eur. J. Pharm."},{"key":"2018_CR56","doi-asserted-by":"crossref","unstructured":"F.A. Verhoeven, H.H. Van der Putten, G. Hennemann, J.M. Lamers, T.J. Visser, M.E. Everts, Uptake of triiodothyronine and triiodothyroacetic acid in neonatal rat cardiomyocytes: effects of metabolites and analogs. J. Endocrinol. 173(2), 247\u2013255 (2002)","DOI":"10.1677\/joe.0.1730247"},{"issue":"2","key":"2018_CR57","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1210\/en.2012-1628","volume":"154","author":"S Horn","year":"2013","unstructured":"S. Horn, S. Kersseboom, S. Mayerl, J. Muller, C. Groba, M. Trajkovic-Arsic, T. Ackermann, T.J. Visser, H. Heuer, Tetrac can replace thyroid hormone during brain development in mouse mutants deficient in the thyroid hormone transporter mct8. Endocrinology 154(2), 968\u2013979 (2013). \n                    https:\/\/doi.org\/10.1210\/en.2012-1628","journal-title":"Endocrinology"},{"issue":"7","key":"2018_CR58","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1210\/jcem.80.7.7608251","volume":"80","author":"T Takeda","year":"1995","unstructured":"T. Takeda, S. Suzuki, R.T. Liu, L.J. DeGroot, Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone. J. Clin. Endocrinol. Metab. 80(7), 2033\u20132040 (1995). \n                    https:\/\/doi.org\/10.1210\/jcem.80.7.7608251","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"2018_CR59","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10456-014-9418-5","volume":"17","author":"SA Mousa","year":"2014","unstructured":"S.A. Mousa, H.Y. Lin, H.Y. Tang, A. Hercbergs, M.K. Luidens, P.J. Davis, Modulation of angiogenesis by thyroid hormone and hormone analogues: implications for cancer management. Angiogenesis 17(3), 463\u2013469 (2014). \n                    https:\/\/doi.org\/10.1007\/s10456-014-9418-5","journal-title":"Angiogenesis"},{"key":"2018_CR60","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.mce.2017.02.029","volume":"458","author":"S Groeneweg","year":"2017","unstructured":"S. Groeneweg, R.P. Peeters, T.J. Visser, W.E. Visser, Therapeutic applications of thyroid hormone analogues in resistance to thyroid hormone (RTH) syndromes. Mol. Cell Endocrinol. 458, 82\u201390 (2017). \n                    https:\/\/doi.org\/10.1016\/j.mce.2017.02.029","journal-title":"Mol. Cell Endocrinol."},{"issue":"7","key":"2018_CR61","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1016\/j.bbagen.2012.08.005","volume":"1830","author":"AM Dumitrescu","year":"2013","unstructured":"A.M. Dumitrescu, S. Refetoff, The syndromes of reduced sensitivity to thyroid hormone. Biochim. Biophys. Acta. 1830(7), 3987\u20134003 (2013). \n                    https:\/\/doi.org\/10.1016\/j.bbagen.2012.08.005","journal-title":"Biochim. Biophys. Acta."},{"issue":"3","key":"2018_CR62","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1172\/JCI84747","volume":"126","author":"E Schoenmakers","year":"2016","unstructured":"E. Schoenmakers, B. Carlson, M. Agostini, C. Moran, O. Rajanayagam, E. Bochukova, R. Tobe, R. Peat, E. Gevers, F. Muntoni, P. Guicheney, N. Schoenmakers, S. Farooqi, G. Lyons, D. Hatfield, K. Chatterjee, Mutation in human selenocysteine transfer RNA selectively disrupts selenoprotein synthesis. J. Clin. Invest. 126(3), 992\u2013996 (2016). \n                    https:\/\/doi.org\/10.1172\/JCI84747","journal-title":"J. Clin. Invest."},{"issue":"2","key":"2018_CR63","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.beem.2007.03.009","volume":"21","author":"CE Schwartz","year":"2007","unstructured":"C.E. Schwartz, R.E. Stevenson, The MCT8 thyroid hormone transporter and Allan-Herndon-Dudley syndrome. Best. Pr. Res Clin. Endocrinol. Metab. 21(2), 307\u2013321 (2007). \n                    https:\/\/doi.org\/10.1016\/j.beem.2007.03.009","journal-title":"Best. Pr. Res Clin. Endocrinol. Metab."},{"issue":"2","key":"2018_CR64","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10456-007-9088-7","volume":"11","author":"SA Mousa","year":"2008","unstructured":"S.A. Mousa, J.J. Bergh, E. Dier, A. Rebbaa, L.J. O\u2019Connor, M. Yalcin, A. Aljada, E. Dyskin, F.B. Davis, H.Y. Lin, P.J. Davis, Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 11(2), 183\u2013190 (2008). \n                    https:\/\/doi.org\/10.1007\/s10456-007-9088-7","journal-title":"Angiogenesis"},{"issue":"12","key":"2018_CR65","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.2217\/nnm.12.200","volume":"8","author":"DJ Bharali","year":"2013","unstructured":"D.J. Bharali, M. Yalcin, P.J. Davis, S.A. Mousa, Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. Nanomed. 8(12), 1943\u20131954 (2013). \n                    https:\/\/doi.org\/10.2217\/nnm.12.200","journal-title":"Nanomed."},{"issue":"10","key":"2018_CR66","first-page":"3825","volume":"29","author":"M Yalcin","year":"2009","unstructured":"M. Yalcin, D.J. Bharali, L. Lansing, E. Dyskin, S.S. Mousa, A. Hercbergs, F.B. Davis, P.J. Davis, S.A. Mousa, Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res. 29(10), 3825\u20133831 (2009)","journal-title":"Anticancer Res."},{"key":"2018_CR67","doi-asserted-by":"publisher","first-page":"S-39","DOI":"10.1089\/thy.1992.2.39","volume":"2","author":"JS LoPresti","year":"1992","unstructured":"J.S. LoPresti, R.S. Dlott, Augmented conversion of T3 to triac (T3AC) is the major regulator of the low T3 state in fasting man. Thyroid 2, S-39 (1992)","journal-title":"Thyroid"},{"issue":"2","key":"2018_CR68","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1210\/me.2006-0035","volume":"21","author":"F Flamant","year":"2007","unstructured":"F. Flamant, K. Gauthier, J. Samarut, Thyroid hormones signaling is getting more complex: STORMs are coming. Mol. Endocrinol. 21(2), 321\u2013333 (2007). \n                    https:\/\/doi.org\/10.1210\/me.2006-0035","journal-title":"Mol. Endocrinol."},{"issue":"7","key":"2018_CR69","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1210\/jc.2011-3399","volume":"97","author":"B Biondi","year":"2012","unstructured":"B. Biondi, L. Wartofsky, Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism? J. Clin. Endocrinol. Metab. 97(7), 2256\u20132271 (2012). \n                    https:\/\/doi.org\/10.1210\/jc.2011-3399","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-02018-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-019-02018-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-02018-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T23:28:07Z","timestamp":1595114887000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-019-02018-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,20]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["2018"],"URL":"https:\/\/doi.org\/10.1007\/s12020-019-02018-4","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,20]]},"assertion":[{"value":"1 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is a review and therefore it does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}